Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2022-09-09 Director's Dealing
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2022-09-09 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-09-09 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-09-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports the entry into a material definitive agreement related to supply and fill/finish services with a partner company. The document does not contain financial statements or detailed financial performance data but rather announces a significant contractual event. Form 8-K filings are typically regulatory filings used to disclose material events and are not annual or quarterly reports, earnings releases, or other specific report types. Therefore, this document fits best under the category of Regulatory Filings (RNS). The document length is 5639 characters, which is consistent with a detailed regulatory announcement rather than a full financial report.
2022-09-01 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 15, 2022, by Protalix BioTherapeutics, Inc. It announces the issuance of a press release with financial results for the quarter ended June 30, 2022, and a business update. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length is 3806 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release or quarterly report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain the full financial report or detailed data.
2022-08-15 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.